Muscular Atrophy, Spinal Clinical Trial
Official title:
Examining the Effects of Trunk Control Training and Pulmonary Rehabilitation Program in Children With Spinal Muscular Atrophy
Verified date | December 2023 |
Source | Istanbul Medipol University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Spinal Muscular Atrophy (SMA) is a severe neuromuscular disorder characterized by the degeneration of alpha motor neurons in the spinal cord, resulting in progressive muscle atrophy and weakness, particularly in proximal and axial muscles. SMA causes respiratory muscle weakness, recurrent infections, and nocturnal hypoventilation, contributing significantly to morbidity and mortality. Children with SMA often display respiratory and trunk muscle weakness compared to healthy controls. Our project aims to investigate the impact of pulmonary rehabilitation, including inspiratory muscle training, along with trunk control exercises in children with SMA. The study will include 30 SMA patients aged 5-18, with maximum inspiratory capacity below 60 centimeters of water (cmH2O), predicted vital capacity over 25%, and the ability to sit unsupported for more than 5 seconds. The participants will be randomly assigned to two groups: Pulmonary Rehabilitation Group (Group 1, n=15) and Trunk Control Training Group (Group 2, n=15). Group 1 will undergo breathing exercises and inspiratory muscle training (IMT), involving diaphragmatic, pursed-lip, and segmental breathing. IMT will be administered with a portable device, starting at appropriate resistance and consisting of 10 cycles, 10 minutes each, once a day, with designated rest intervals. Also applied by calculating 30% of the maximal inspiratory pressure (MIP). During weekly clinic visits, the MIP value will be recalculated and the current threshold pressure value will be determined. In Group 2, alongside pulmonary rehabilitation, children will engage in trunk control exercises, progressively increasing in difficulty, focusing on pelvic control, proximal stabilization, and strengthening trunk and gluteal muscles. All interventions will be performed in front of a mirror. At the end of the 8-week intervention, MIP and Maximal Expiratory Pressure (MEP) will be used to measure respiratory muscle performance, spirometry will be used to monitor lung volume changes, and Peak Cough Flow will be used to evaluate the effectiveness of cough. The Trunk Control Measurement Scale, the Revised Upper Extremity Module, and the Children's Quality of Life Scale will assess trunk control, upper extremity functions, and quality of life, respectively. The Hammersmith Functional Motor Scale will assess gross motor functions and the Zarit Caregiver Burden Scale will inquire about familial factors affecting the child.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | December 1, 2024 |
Est. primary completion date | July 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 18 Years |
Eligibility | Inclusion Criteria: - Those with genetic documentation of 5q spinal muscular atrophy (SMA) homozygous gene deletion, mutation, or compound heterozygote and who have been clinically diagnosed with SMA, - Those between the ages of 5-18, - Having a predicted vital capacity greater than 25%, - Maximum inspiratory capacity is less than 60 cmH2O, - Children who can sit unsupported for at least 5 seconds and who have no or 3 weeks of acute reversible events affecting the upper respiratory tract. Exclusion Criteria: - Having had upper extremity and spine surgery, - Having other orthopedic and neurological problems, - Having cognitive impairments that may prevent understanding simple verbal commands, - Having visual or auditory disabilities, - Premature birth |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul Medipol Mega Hospital | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Istanbul Medipol University Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Inspiratory Muscle Strength | Inspiratory Muscle Strength will be assessed by the Maximal Inspiratory Pressure (MIP). For MIP measurement, participants will be asked to perform maximum inspiration starting from the residual lung volume following maximum expiration to the total lung capacity. | 8 weeks | |
Primary | Expiratory Muscle Strength | Expiratory Muscle Strength will be assessed by the Maximal Expiratory Pressure (MEP). For MEP measurement, participants will be asked to exert maximum expiratory effort from total lung capacity to residual volume. Pressure thresholds sustained for at least 1 second will be recorded. The highest pressure value of these maneuvers, expressed in cmH2O, will be recorded. | 8 weeks | |
Primary | Pulmonary Function Test | Participants will be in a sitting position during spirometric measurement in accordance with the standards and recommendations of the American Thoracic Society and European Respiratory Society statement. Forced vital capacity (FVC), volume of air exhaled in the 1st second of forced expiration (FEV1), FEV1/FVC ratio, peak expiratory flow (PEF) values of the participants will be measured through spirometric (Spirobank MIR, Italy) measurement. At least three successful spirometric assessments will be recorded. FVC is the volume of air exhaled rapidly and forcefully following deep inspiration. PEF value is measured by maximum inspiration followed by maximum expiration. It usually correlates with FEV1 measurements. In the interpretation of spirometric tests, information can be obtained about the type and severity of respiratory dysfunction by looking at the shape and numerical parameters of the flow-volume and time curve. | 8 weeks | |
Primary | Effectiveness of Cough | The effectiveness of the cough will be evaluated with a Peak Flow meter. This value provides us with information about the expiratory muscles. To evaluate the ability to cough without assistance, the patient is asked to cough as hard as possible into a small handheld device called a peak flow meter (ExpiritePeak Flow Meter DL-F03) while in a sitting position. This measured value is called peak cough flow (PCF). These values will provide an indication of the patient's disease progression, ability to clear secretions, and risk of developing respiratory complications. PCF is applied to children over the age of 4-8. The expected value in healthy individuals is PCF = 360 L/minute. The fact that this value is 270 L/minute in children with DMD, another neuromuscular muscle disease, shows that participants have adequate cough. A PCF value falling below 160 L/minute indicates inadequate airway clearance. Absolute values will be determined by selecting the largest of three consecutive trials. | 8 weeks | |
Secondary | Trunk Control | Trunk Control will be assessed by Trunk Control Measurement Scale. Children's trunk control levels will first be determined according to the Trunk Control Measurement Scale (TCMS), which was developed for children with cerebral palsy. The TCMS consists of 15 items that evaluate 2 different parameters related to trunk control; One of the parameters is static sitting balance and the other is dynamic sitting balance. It evaluates not only trunk control but also trunk compensation during limb movements. Within dynamic sitting balance, balance parameters in reaching and reaching are also evaluated. Total scores range from 0 to 58, with higher scores indicating good trunk control. | 8 weeks | |
Secondary | Upper Extremity Functions | Upper Extremity Functions will be assessed by Revised Upper Limb Module for Spinal Muscular Atrophy. The revised upper extremity module for SMA contains 19 items and is evaluated out of a total of 37 points. The first item is not included in the scoring, and the remaining 18 items are evaluated between 0-2 points, except for item I, and only item I is evaluated between 0-1 points. The module is calculated on a total of 37 points, higher scores indicate better upper extremity function. | 8 weeks | |
Secondary | Chest volume | Data recording will be created using chest radiography to examine changes in lung volumes. | 8 weeks | |
Secondary | Gross Motor Function | Gross Motor Function levels will ve assessed by the Hammersmith Functional Motor Scale. It measures the motor function changes of children with SMA who can and cannot walk. It consists of 33 items that indicate the capacity to perform motor functions such as sitting on a chair without support, lying face down or rolling over, lifting the head from the prone position, and crawling. Each activity, categorized into items, is scored on a 3-point system with 2 points for "performs without modification", 1 point for "performs with modification/adaptation/compensation" and 0 points for "cannot perform the task". The maximum score on the scale is 66, and a higher score means better motor functions. | 8 weeks | |
Secondary | Quality of Life of the Children | In evaluating the quality of life of patients with SMA; Pediatric Quality of Life Questionary-Generic Core (PedsQL-GC) will be used. It questions the areas of physical health, emotional functionality, and social functionality, which are the characteristics of the state of health defined by the World Health Organization. Items are scored between 0-100. If the answer to the question is marked as never, it receives 0=100, if it is marked as rarely, it receives 1=75, if it is marked as sometimes, it receives 2=50, if it is marked as often, it receives 3=25, and if it is marked as almost always, it receives 4=0 points. The total score is obtained by adding the points and dividing by the number of items completed. If more than 50% of the scale is not filled out, the scale is not evaluated. The higher the total score, the better the health-related quality of life is perceived. | 8 weeks | |
Secondary | Burden of Caregiver | Caregiver burden score will be evaluated by the Zarit Caregiver Burden Interview. It was developed by Zarit, Reever and Bach-Peterson in 1980. It is a scale used to evaluate the distress experienced by caregivers of individuals in need of care. The scale, which can be completed by asking the caregivers themselves or the researcher, consists of 19 statements that determine the impact of caregiving on the individual's life. The scale has a Likert-type rating ranging from 1 to 5, such as never, rarely, sometimes, often or almost always. A high scale score indicates that the distress experienced is high. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00533221 -
Pilot Study of Growth Hormon to Treat SMA Typ II and III
|
Phase 2 | |
Completed |
NCT02908685 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
|
Phase 2 | |
Recruiting |
NCT05575011 -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115
|
Phase 1 | |
Completed |
NCT05073133 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
|
Phase 4 | |
Terminated |
NCT02240355 -
A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)
|
Phase 1 | |
Recruiting |
NCT05042921 -
Pediatric Spinal Muscular Atrophy (SMA) China Registry
|
||
Completed |
NCT04419233 -
Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection
|
||
Recruiting |
NCT05861986 -
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
|
Phase 4 | |
Completed |
NCT00466349 -
International SMA Patient Registry
|
||
Completed |
NCT03920865 -
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
|
Phase 1 | |
Recruiting |
NCT05481164 -
Newborn Screening for Spinal Muscular Atrophy
|
||
Completed |
NCT04089566 -
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
|
Phase 3 | |
Recruiting |
NCT05861999 -
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
|
Phase 4 | |
Recruiting |
NCT05755451 -
Natural History of SMA
|
||
Active, not recruiting |
NCT01233817 -
Progressive Strength Training in Spinal Muscular Atrophy
|
N/A | |
Recruiting |
NCT04317794 -
Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)
|
||
Active, not recruiting |
NCT05618379 -
Adult Spinal Muscular Atrophy (SMA) China Registry
|
||
Active, not recruiting |
NCT04488133 -
A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec
|
Phase 4 | |
Completed |
NCT03781479 -
Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
|
Phase 2 | |
Completed |
NCT00568698 -
A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
|
Phase 1/Phase 2 |